Investors

Press Releases

 
Press Releases
  Date Title View
Mar 13, 2017
JERSEY CITY, N.J., March 13, 2017 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a drug development company committed to the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs, today reported financial results for the year ended December 31, 2016, and provided an update on recent oper...
Mar 7, 2017
JERSEY CITY, N.J., March 07, 2017 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (NASDAQ:SCYX) today announced that the Company will present at the 29th Annual ROTH Conference at the Ritz Carlton Laguna Niguel in Dana Point on Tuesday, March 14, 2017 at 5:30 p.m. PT. A live webcast wi...
Mar 2, 2017
JERSEY CITY, N.J., March 02, 2017 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced that the United States Food and Drug Administration (FDA) has informed the Company to hold the initiation of any new clinical studies with the intravenous (IV) formulation of SCY-078 until the FDA completes a review of ...
Jan 31, 2017
JERSEY CITY, N.J., Jan. 31, 2017 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (NASDAQ:SCYX) today announced that the Company will participate in the following upcoming investor conferences: Canaccord Genuity Rare Disease Conference at the InterContinental New York Barclay Hotel in...
Jan 26, 2017
— Former Chief Operating Officer of Medivation adds broad experience in commercial, strategy, operations and business development — — SCYNEXIS to ramp up commercial preparatory and territorial licensing activities for its lead product, SCY-078 — JERSEY CITY, N...
Dec 13, 2016
— Regimen of intravenous (IV) formulation of SCY-078 successfully identified and characterized to support subsequent studies — — Long-term toxicology studies completed, confirming favorable safety profile of oral SCY-078 — ...
Dec 12, 2016
JERSEY CITY, N.J., Dec. 12, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (NASDAQ:SCYX), a pharmaceutical company developing novel anti-infectives to address unmet therapeutic needs, today announced that the Company will participate in the Guggenheim Securities 4th Annual Boston Healthcare Conf...
Nov 7, 2016
-- Positive Results From Multiple Studies Provide Clear Evidence of Clinical Antifungal  Activity and Favorable Safety Profile of  SCY-078 -- -- Company is Well Positioned and Capitalized to Accelerate and Expand Clinical Development of SCY-078 in Multiple Indications --...
Oct 25, 2016
SCY-078 demonstrates a low potential for certain drug-drug interactions — a relevant differentiator versus the azoles, the leading antifungal class — providing an opportunity for favorable labeling Significant step forward to further de-risk the ongoing development program of...
Oct 5, 2016
Study Results Confirm Overall Antifungal Activity of Oral SCY-078 in Patients with Candida InfectionsWell-Tolerated and Active Oral Dose of SCY-078 Identified for Invasive Candidiasis Patients...
1
... NextLast
= add release to Briefcase